ClinicalTrials.gg
Active, not recruitingNCT02808780OPALUpdated Nov 3, 2026

An Observational Prospective Long-term Exposure Registry of Adult Patients With Moderate-to-Severe Ulcerative Colitis

An observational study in Ulcerative Colitis, sponsored by Janssen Biotech, Inc.. Active, not recruiting at 63 sites in 9 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-03.

Sponsored by Janssen Biotech, Inc. (part of Johnson & Johnson) · Observational

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
535
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 43 studies in Colitis, Ulcerative by Johnson & Johnson — 12 open to participants now, 21 under way, 8 of them phase 3. Colitis, Ulcerative · Johnson & Johnson.

Enrollment
3rd of 15
535 · median 200
Started
2016
the only one that year
Observational
15 of 43
9 open now
Primary completion
2026-12
later than 4 of 20 live
Registered
17th of 43
by date

Among the 43 studies in Colitis, Ulcerative by Johnson & Johnson, this one is the 3rd largest by enrollment of the 15 observational ones that give a count, is the only one that started in 2016, is one of 15 observational ones, reaches primary completion later than 4 of the 20 other live ones, and was the 17th registered.

Colitis, Ulcerative

1,857 studies on the registry are indexed under Colitis, Ulcerative; 472 are open to participants now.

Browse Colitis, Ulcerative studies →

Open to participants now

12 of the 43 studies in Colitis, Ulcerative by Johnson & Johnson are open now, in 12 countries. Recruiting first, the newest first:

7 more — sign in →

By country, each count listing its studies:

All 12 open studies →

Who these studies take

Of the 305 Colitis, Ulcerative studies recruiting now, 135 (44%) set no upper age limit and 134 (44%) stop at 75 or younger; 70 take children under 18; 41 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 43 studies in Colitis, Ulcerative by Johnson & Johnson, or all of them as a file.
02

Study summary

The purpose of this study is to describe the long-term safety risks in adult participants with moderate-to-severe ulcerative colitis who are treated with Simponi.

03

Conditions studied

  • Ulcerative Colitis

Keywords

  • Ulcerative Colitis
  • Simponi (Golimumab)
  • Thiopurines
  • Lymphoma
  • Malignancies
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Probability sample

Study population

Participants with moderate-to-severe ulcerative colitis for at least 3 months prior to enrollment will be observed

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Have moderate-to-severe ulcerative colitis of at least 3 months' duration prior to enrollment, confirmed by endoscopy at any time in the past
  • For enrollment into the Simponi-exposed cohort meets one of the following:

    1. The participant is currently receiving Simponi ,or
    2. The participant is continuing to receive Simponi after participation in an ulcerative colitis study, or
    3. The participant is scheduled to receive Simponi within 30 days after enrollment
  • For Thiopurine cohort:

    1. The participant is currently receiving thiopurines, having received at least 12 consecutive weeks of therapy prior to registry entry
    2. Participant must not be receiving other approved biologic agents, including Simponi, or any agents at enrollment
    3. Participant may have received biologics other than Simponi or investigational agents prior to enrollment

Exclusion criteria

Exclusion Criteria:

  • Participants who cannot be treated with Simponi or thiopurines
  • Participants with a previous diagnosis of lymphoma or hematologic at any time prior to enrollment
  • Participants currently receiving an or biologic agent other than Simponi
  • Participants with any condition for which, in the opinion of the investigator, participation in the registry would not be in the best interest of the participant or that could prevent, limit, or confound the protocol-specified assessments
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
535 participants (actual)
Patient registry
No

Groups and cohorts

  • Simponi-exposed cohort

    Participants receiving Simponi at enrollment and are still receiving Simponi after participation in a therapeutic trial or participants scheduled to receive Simponi within 30 days after enrollment. Participants in this cohort may be receiving Simponi alone or in combination with thiopurines but must not be receiving other approved biologics or investigational agents at enrollment. Participants may have received other approved biologics or investigational agents prior to enrollment.

  • Thiopurine cohort

    Participants currently receiving thiopurines, having received at least 12 consecutive weeks of therapy prior to registry entry. Participants must not be receiving approved biologic agents, including Simponi, or investigational agents at enrollment. These patients may have received biologics other than Simponi or investigational agents prior to enrollment.

06

What researchers measure

Primary outcomes

  1. Long-term Safety: Participants with Adverse Events of Interest (AEIs) and Serious Adverse Events (AEs) Including Malignancies, Pregnancies, and Non-serious Malignancies

    Descriptive analysis of serious adverse events, adverse events of interest (including lymphoma \& other malignancies), pregnancies, and non-serious malignancies in participants less than (\<) 30 years of age will be reported.

    Time frame: 6 years

Secondary outcomes

  1. Clinical Disease Status as Assessed by Partial Mayo Score

    The partial Mayo score, a validated tool used to assess disease status in participants with ulcerative colitis, will be utilized to assess clinical status in this registry. Information will be obtained using 3 of the individual components of the full Mayo score, including stool frequency, rectal bleeding, and PGA (Physician's Global Assessment). Each component score ranges from 0 (normal) to 3 (severe disease) and the score is the sum of those three categories. The total Partial Mayo Score will be calculated as the sum of the scores of all 3 components for each participant that ranges from 0-9.

    Time frame: 6 years

  2. Short Inflammatory Bowel Disease Questionnaire (SIBDQ) Score

    The SIBDQ is a disease-specific health-related quality of life (HRQoL) questionnaire, able to detect and define meaningful clinical changes in inflammatory bowel disease (IBD) patients by measuring physical, social and emotional status. The total score ranges from 10 (worst health) to 70 (best health).

    Time frame: 6 years

  3. EuroQoL-5 Dimensions-5 Levels (EQ-5D-5L) Score

    The EQ-5D-5L is a standardized non-disease specific instrument for describing and assessing health-related quality of life.This instrument evaluates 5 areas including mobility, ability for self-care, ability in usual activities, pain/discomfort and anxiety/depression.There also is a self-evaluated 100-point health assessment.

    Time frame: 6 years

  4. Work Productivity and Activity Impairment Questionnaire - Ulcerative Colitis (WPAI-UC)

    The WPAI-UC is a validated instrument that measures the effect of ulcerative colitis (UC) symptoms on a patient's life (eg, diarrhea, loss of appetite, weight loss, abdominal pain, fever, joint pain, skin sores, rectal bleeding) and on his or her ability to work and perform regular activities.

    Time frame: 6 years

  5. Treatment Satisfaction Questionnaire for Medication (TSQM) Score

    The TSQM is a 14-question instrument that gauges a patient's experience with his or her medication.The questionnaire was designed to evaluate the effectiveness, side effects, and convenience of the medication over a period of 2- to 3-weeks or since the last time it was taken.

    Time frame: 6 years

  6. Health Care Utilization: Evaluate the Number of Each Hospitalizations in Participants in Each Cohort

    Number of hospitalizations in participants in each cohort will be reported.

    Time frame: 6 years

  7. Health Care Utilization: Evaluate the Reasons for Hospitalization in Participants in Each Cohort

    Reasons for hospitalization in participants in each cohort will be reported.

    Time frame: 6 years

07

Study locations

63 sites
  • Murrieta, California, United States
  • Rialto, California, United States
  • Ventura, California, United States
  • Coral Gables, Florida, United States
  • Fort Myers, Florida, United States
  • Lake Worth, Florida, United States
  • Lauderdale Lakes, Florida, United States
  • Miami, Florida, United States
  • Tampa, Florida, United States
  • Suwanee, Georgia, United States
  • Chicago, Illinois, United States
  • Sylvania, Ohio, United States
  • Pittsburgh, Pennsylvania, United States
  • Houston, Texas, United States
  • San Antonio, Texas, United States
  • Lansdowne Town Center, Virginia, United States
  • Salzburg, Austria
  • Sankt Poelten Noe, Austria
  • Vienna, Austria
  • New Westminster, British Columbia, Canada
  • Vancouver, British Columbia, Canada
  • Oshawa, Ontario, Canada
  • Ottawa, Ontario, Canada
  • Pilsen, Czechia
  • Clermont-Ferrand, France
  • Clichy, France
  • Créteil, France
  • Grenoble, France
  • Montpellier, France
  • Nice, France
  • Pierre-Bénite, France
  • Saint-Priest-en-Jarez, France
  • Strasbourg, France
  • Berlin, Germany
  • Dessau Roblau, Germany
  • Halle, Germany
  • Hamburg, Germany
  • Heidelberg, Germany
  • Kiel, Germany
  • Leipzig, Germany
  • Ludwigshafen, Germany
  • Lyneburg, Germany
  • München, Germany
  • Saarbrücken, Germany
  • Athens, Greece
  • Heraklion, Greece
  • Ioannina, Greece
  • Thessaloniki, Greece
  • Busan, South Korea
  • Gyeonggi-do, South Korea
  • Seongnam-si, South Korea
  • Seoul, South Korea
  • A Coruña, Spain
  • Barcelona, Spain
  • Córdoba, Spain
  • Fuenlabrada, Spain
  • Huelva, Spain
  • Madrid, Spain
  • Majadahonda, Spain
  • San Sebastián de los Reyes, Spain
  • Valencia, Spain
  • Vigo, Spain
  • Zaragoza, Spain
08

Timeline

2 registry updates since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Dec 2016 (actual). Primary completion is estimated for Dec 2026, 119 months after the start.

Of 83 industry-sponsored observational studies under Colitis, Ulcerative, half reached primary completion within 44 months of starting (the median), counting those still running; a quarter within 28 and three quarters within 72. This study's planned 119 months is above that.

Counting every sponsor, half of 271 studies reached it within 47 months; a quarter within 29 and three quarters within 90.

How these figures are worked out, and which studies are left out of them.

Registered
May 30, 2016
First posted
Jun 22, 2016
StartActual
Dec 16, 2016
Primary completionEst.
Dec 10, 2026
CompletionEst.
Mar 11, 2027
Last update
Nov 3, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Minor edits
Nothing that changes what the study is or who can join. Edited: verification date
2 updates, last Nov 3, 2026
Show all 2 updates
  1. Nov 3, 2026
    Minor edits only
    + 1 other change: verification date
  2. Sep 25, 2026
    Minor edits only
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT02808780
Responsible party
Sponsor
First posted
Jun 22, 2016
Start date
Dec 16, 2016
Primary completion
Dec 10, 2026 (estimated)
Completion
Mar 11, 2027 (estimated)
Last update
Nov 3, 2026

Study contacts

Janssen Biotech, Inc. Clinical Trial
study director · Janssen Biotech, Inc.

Oversight

Data monitoring committee
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion